Last updated: August 13, 2026
Mifepristone has two distinct U.S. pharmaceutical markets. The larger-volume market is medication abortion, where Mifeprex and generic mifepristone compete with misoprostol-only regimens and procedural abortion. The higher-value market is Korlym for hyperglycemia associated with endogenous Cushing's syndrome, where Corcept Therapeutics has historically controlled the branded market. Revenue visibility is limited because Danco Laboratories and GenBioPro are privately held, while Corcept reports company-level rather than fully disaggregated product data. FDA regulatory changes have expanded dispensing access, but litigation, state restrictions, controlled distribution requirements, and manufacturing capacity continue to shape commercial performance.
Mifepristone Market Dynamics, Patent Position, FDA Status, and Financial Trajectory
What is the current mifepristone market structure?
Mifepristone is marketed in the United States through two principal product pathways:
| Product |
Active ingredient and strength |
Indication |
Sponsor or manufacturer |
Market position |
| Mifeprex |
Mifepristone 200 mg |
Medication abortion through 70 days' gestation, used with misoprostol |
Danco Laboratories |
Originator abortion product |
| Generic mifepristone |
Mifepristone 200 mg |
Medication abortion through 70 days' gestation |
GenBioPro |
FDA-approved generic |
| Korlym |
Mifepristone tablets, primarily 300 mg |
Hyperglycemia secondary to endogenous Cushing's syndrome |
Corcept Therapeutics |
Branded specialty product |
Mifeprex was approved by the FDA in 2000 under NDA 020687. The FDA approved the first generic mifepristone product from GenBioPro in 2019.[1,2] Korlym received FDA approval in 2012 under a separate NDA for a rare endocrine indication.[3]
The two markets have different economics. Medication abortion is a high-volume, lower-price market exposed to pharmacy access, state-level restrictions, telehealth policy, and generic competition. Korlym is a lower-volume, high-price specialty product supported by reimbursement services, prescriber concentration, and the small population with endogenous Cushing's syndrome.
How large is the mifepristone market?
Public data do not provide a single reliable revenue figure for all mifepristone products. The market must be estimated by segment.
Medication abortion market
The United States has experienced sustained growth in medication abortion. The Guttmacher Institute reported that medication abortion accounted for approximately 63% of abortions obtained in formal U.S. health-care settings in 2023, up from roughly half several years earlier.[4] Mifepristone plus misoprostol is the dominant FDA-approved medication-abortion regimen.
Commercial value is difficult to measure because:
- Danco is privately held and does not publish audited product revenue.
- GenBioPro is privately held and does not disclose U.S. sales.
- Prices vary by clinic, mail-order provider, pharmacy, payer, and state.
- Many providers purchase product through institutional or nonprofit channels.
- Mifepristone is often bundled economically with misoprostol, clinical services, laboratory testing, and telehealth.
Demand is driven more by procedure volume and access than by conventional prescription-market expansion. The principal growth variables are the share of abortions performed with medication, dispensing through retail pharmacies, telehealth adoption, and substitution away from branded Mifeprex toward generic product.
Korlym market
Corcept reported total revenue of approximately $482 million in 2023, with Korlym historically representing the company's commercial base.[5] The company does not present Korlym as a separately reported revenue line in the same way a diversified pharmaceutical company would report a major product segment.
Korlym revenue depends on:
- Diagnosis of endogenous Cushing's syndrome.
- Identification of patients with hyperglycemia who are not adequately controlled by other treatments.
- Specialist prescribing by endocrinologists.
- Reimbursement approvals and patient-support programs.
- Persistence on therapy.
- Competition from steroidogenesis inhibitors and other medical treatments for Cushing's syndrome.
Korlym's price and specialty-drug economics are materially different from the abortion market. A relatively small number of patients can support substantial revenue if treatment duration and reimbursement remain stable.
What is the financial trajectory for mifepristone products?
The financial trajectory is bifurcated.
Mifeprex and generic mifepristone
Mifeprex faces long-term unit-share pressure from generic mifepristone. The 2019 generic approval created a second FDA-approved supplier, although market penetration has been constrained by distribution practices, policy disputes, and provider purchasing decisions.
The main commercial pattern is likely to be:
- Continued growth in total medication-abortion demand.
- Rising use of telehealth and mail-order dispensing.
- Increasing generic substitution where providers and pharmacies can source generic product.
- Persistent geographic fragmentation caused by state laws.
- Price compression in procurement markets, offset partly by volume growth.
The removal of the in-person dispensing requirement in 2021 and the January 2023 FDA changes permitting certified retail pharmacies to dispense mifepristone expanded potential distribution channels.[6,7] These changes improve market access but do not eliminate state restrictions or litigation risk.
Korlym
Corcept's revenue trajectory has historically benefited from:
- A protected specialty indication.
- High treatment value in a rare disease.
- Direct commercial infrastructure focused on endocrinology.
- Patient-support and reimbursement programs.
- Limited direct branded competition for the exact approved use.
The principal medium-term risks are relacorilant development and commercialization, potential payer pressure, alternative Cushing's treatments, and patent or regulatory challenges. Relacorilant is a selective glucocorticoid receptor modulator in development by Corcept and is intended to broaden the company's Cushing's syndrome franchise, but it is not interchangeable with mifepristone and does not have the same FDA approval status unless and until approved.[5]
What is the FDA regulatory status of mifepristone?
Mifepristone has separate FDA labeling and risk-management histories for Mifeprex and Korlym.
Mifeprex FDA status
Mifeprex is approved with misoprostol for medical termination of intrauterine pregnancy through 70 days' gestation. The product has been subject to a Risk Evaluation and Mitigation Strategy, or REMS.
The FDA modified the Mifeprex REMS in January 2023. The principal changes included:
- Removal of the in-person dispensing requirement.
- Permission for certified pharmacies to dispense mifepristone.
- Continued requirements for prescriber and pharmacy certification.
- Continued use of a patient agreement and safety-related controls.
The FDA's action followed data supporting the established safety profile of medication abortion when used according to labeling.[7]
Korlym FDA status
Korlym is approved for adults with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have failed surgery. Its label includes important contraindications, including pregnancy-related restrictions and interactions with drugs metabolized through CYP3A.[3]
Korlym is distributed through a controlled specialty-pharmacy model. Its commercial system is designed around prescriber identification, reimbursement authorization, patient monitoring, and drug-interaction management.
What patents protect mifepristone products?
The core mifepristone compound is old and is not protected in the United States by a long-lived composition-of-matter patent. The commercial patent analysis therefore turns on product-specific formulations, methods of use, dosing, manufacturing, and regulatory exclusivity.
Mifeprex patent position
Mifeprex's original regulatory exclusivity and product protection have expired. The key barriers to competition are now primarily regulatory and commercial:
- FDA approval requirements for ANDA or other abbreviated pathways.
- REMS-related certification and distribution compliance.
- Manufacturing qualification.
- Provider and pharmacy relationships.
- Litigation and state-level access restrictions.
- Brand recognition and procurement contracts.
The existence of a generic FDA approval confirms that the core product is legally vulnerable to generic competition. The commercial strength of Mifeprex is therefore weaker than that of a newly approved small molecule with active composition patents.
Korlym patent position
Korlym's protection is more dependent on use-specific and product-specific rights than on the mifepristone molecule itself. Potentially relevant rights can include:
- Use of mifepristone to treat Cushing's syndrome-associated hyperglycemia.
- Dosing regimens.
- Tablet formulations.
- Manufacturing and analytical processes.
- Drug-interaction management.
- Follow-on indications or patient-selection methods.
The enforceability and remaining life of each patent must be assessed from current USPTO records, Orange Book entries, issued claims, terminal disclaimers, and litigation history. Patent term cannot be inferred solely from the age of mifepristone because Korlym-related rights may have been filed decades after the original compound patents.
What is the Orange Book status of Mifeprex and Korlym?
Mifeprex and Korlym are prescription drugs with FDA-approved labeling, but their Orange Book treatment and patent listings must be analyzed by NDA and product rather than by active ingredient alone.
Mifeprex's generic competition demonstrates that at least one ANDA pathway has been approved. A listed patent can still affect later ANDA timing, but the presence of a listed patent does not by itself prevent approval or guarantee an enforceable exclusivity period.
Korlym's Orange Book position is commercially more important because Corcept has a specialty product with a higher per-patient economic value. Listed patents covering indication, dosage, formulation, or other product characteristics may create a later generic-entry date even where the active ingredient itself is old.
A complete current patent table requires a live Orange Book and USPTO review. The available public record supports a conclusion that Mifeprex's principal composition protection is exhausted, while Korlym's remaining protection depends on product-specific rights and their expiration dates.
When does mifepristone lose exclusivity?
Mifepristone's original compound exclusivity has already expired. The relevant dates are product-specific:
| Exclusivity category |
Mifepristone status |
| Original compound patent |
Expired |
| Mifeprex FDA approval |
2000 |
| First FDA-approved generic |
2019 |
| Mifeprex REMS |
Modified, not eliminated |
| Korlym approval |
2012 |
| Korlym product and method protection |
Must be assessed patent by patent |
Regulatory exclusivity and patent exclusivity are different. The expiration of a compound patent does not remove the need for FDA approval, and a REMS can continue after patent expiry. Conversely, a patent covering an approved method or formulation can delay a generic even when the underlying molecule is old.
Which companies are challenging or competing with mifepristone?
Medication abortion competitors
The competitive set includes:
- GenBioPro, the FDA-approved generic mifepristone supplier.
- Danco Laboratories, the Mifeprex sponsor.
- Misoprostol-only providers and manufacturers.
- Telehealth abortion providers.
- Clinics and pharmacy networks dispensing medication abortion.
- Surgical abortion providers.
Misoprostol-only treatment is a clinical substitute but does not contain mifepristone. It can become more important when access to mifepristone is disrupted, although regimen efficacy, dosing, side effects, and clinical workflows differ.
Cushing's syndrome competitors
Korlym competes indirectly with:
- Osilodrostat.
- Metyrapone.
- Ketoconazole.
- Pasireotide.
- Surgery.
- Other investigational glucocorticoid receptor modulators.
These products do not all share the same mechanism. Some reduce cortisol synthesis, while mifepristone blocks the glucocorticoid receptor. Treatment choice depends on disease severity, surgery status, glucose control, contraindications, drug interactions, and physician preference.
What patent litigation affects mifepristone?
The most consequential recent litigation involved FDA approval and regulation of Mifeprex.
In Alliance for Hippocratic Medicine v. FDA, a federal district court challenged the FDA's original approval and later regulatory actions. The Fifth Circuit narrowed but did not eliminate the challenge. In June 2024, the U.S. Supreme Court reversed on standing grounds, holding that the plaintiffs lacked standing to challenge FDA actions.[8]
The decision preserved FDA approval and the current federal regulatory framework. It did not resolve all state-level restrictions or prevent future litigation by parties with standing.
For commercial planning, the litigation outcome reduced immediate federal invalidation risk but did not eliminate:
- State-level restrictions.
- Enforcement disputes involving shipment and dispensing.
- Political changes affecting abortion access.
- Provider and pharmacy risk tolerance.
- Potential future challenges to FDA policy.
How strong is the mifepristone patent estate?
The patent estate is structurally stronger for Korlym than for Mifeprex, but neither product has a strong current composition-of-matter position.
Mifeprex
Mifeprex has low patent strength and high regulatory and political exposure. Its defenses are based on FDA status, manufacturing, distribution, provider networks, and market access rather than a durable compound patent.
Korlym
Korlym has moderate product-level protection potential, depending on the scope and remaining term of issued patents. Its commercial defenses include:
- Narrow approved indication.
- Specialist prescribing.
- Reimbursement complexity.
- Patient-monitoring requirements.
- Limited patient population.
- Proprietary commercial infrastructure.
The main weakness is that mifepristone is an old active ingredient. A generic applicant can potentially challenge use, formulation, or other listed claims through Paragraph IV certification, subject to the specific patents listed for the relevant NDA.
What generic entry risks exist for Mifeprex and Korlym?
Mifeprex generic-entry risk
Generic entry is already established. The remaining question is share allocation rather than whether generic competition can occur. Risk to Danco includes:
- Lower acquisition cost for providers.
- Pharmacy substitution.
- Increased supplier bargaining power.
- Potential additional generic entrants.
- Greater price transparency.
Danco may retain share through established supply relationships, product familiarity, and provider preference, but these factors do not create patent exclusivity.
Korlym generic-entry risk
Korlym faces a later and more complex generic threat. A prospective ANDA applicant could challenge listed patents through Paragraph IV certification. Possible entry scenarios include:
| Scenario |
Commercial effect |
| No successful challenge |
Continued branded pricing until patent expiry or settlement date |
| Paragraph IV litigation with settlement |
Entry on an agreed date, potentially before full patent expiry |
| Successful invalidity or non-infringement challenge |
Earlier generic entry and sharp price pressure |
| Skinny-label entry |
Generic launch for non-protected indications while avoiding protected use |
| Regulatory delay |
Extended branded share despite patent challenge |
Because Korlym revenue is concentrated in a rare disease, generic entry could cause a rapid decline in sales even if patient volume remains stable.
What licensing deals affect mifepristone?
The principal commercial rights are held through sponsor and manufacturer relationships rather than a broad public licensing market.
- Danco commercializes Mifeprex in the United States under its product rights and supply arrangements.
- GenBioPro markets its own FDA-approved generic.
- Corcept controls Korlym commercialization.
- Publicly visible licensing activity around mifepristone has not created a diversified global branded market comparable with large oncology or immunology products.
Mifepristone's commercial value is therefore concentrated in distribution control, regulatory approvals, manufacturing capacity, and clinical access rather than in royalty-bearing platform licenses.
What manufacturing and geographic barriers affect the market?
Manufacturing capacity is strategically important because mifepristone is politically sensitive and has a limited number of established U.S. suppliers. Supply disruption can affect market access even when demand is strong.
Geographic coverage is fragmented:
- Federal FDA approval applies nationally.
- State abortion laws determine practical availability.
- Pharmacy certification and dispensing policies affect channel access.
- Telehealth legality and shipment rules vary by jurisdiction.
- International markets use different regulators, labeling, and procurement systems.
For Korlym, geographic exposure is less politically fragmented but remains dependent on U.S. specialty reimbursement and endocrine referral patterns. The product's rare-disease economics make international expansion more dependent on country-specific pricing and reimbursement decisions.
What is the outlook for mifepristone revenue?
The medication-abortion segment is likely to show volume growth but increasing price and access variability. Generic penetration should pressure branded unit economics, while total market growth may offset part of that pressure for suppliers with efficient manufacturing and broad distribution.
Korlym has a different trajectory. It can sustain high revenue per patient while the diagnosis and treatment market expands, but its downside is concentrated around generic entry, competitive endocrine therapies, payer restrictions, and replacement by future Corcept products.
The central investment distinction is this: Mifeprex is a volume-and-access market with limited patent protection, while Korlym is a specialty-price market with greater product-level commercial defensibility but higher concentration risk.
Key Takeaways
- Mifepristone has two separate U.S. businesses: medication abortion and Korlym for Cushing's syndrome-associated hyperglycemia.
- Mifeprex's core compound protection has expired, and generic competition is already established.
- FDA changes in 2023 expanded pharmacy dispensing and improved distribution flexibility.
- The Supreme Court's 2024 standing decision preserved federal FDA approval and the current national framework.
- Danco and GenBioPro do not publicly disclose detailed revenue, so the abortion-market financial trajectory must be inferred from procedure volume, channel expansion, and generic share.
- Corcept reported approximately $482 million in 2023 company revenue, historically driven mainly by Korlym.
- Korlym's commercial protection depends on indication, formulation, method-of-use, and other product-specific patents rather than the old mifepristone molecule.
- Generic entry would likely have a larger percentage impact on Korlym revenue than on the broader medication-abortion market because Korlym revenue is concentrated in one specialty product.
- Misoprostol-only treatment, procedural abortion, steroidogenesis inhibitors, surgery, and investigational glucocorticoid receptor modulators are the main competitive alternatives.
- Regulatory and geographic access barriers are more important to Mifeprex economics than remaining compound patents.
FAQs
Is mifepristone a biologic or a small-molecule drug?
Mifepristone is a synthetic small-molecule drug. Biosimilar regulation does not apply. Competition proceeds through generic-drug pathways, including ANDA approval.
Does the FDA approval of generic mifepristone eliminate Mifeprex's market?
No. Generic approval creates direct competition but does not remove the branded product. Mifeprex can retain customers through supply relationships, provider familiarity, distribution arrangements, and contracting.
Can mifepristone be dispensed by retail pharmacies?
Yes. Following the FDA's January 2023 REMS modification, certified retail pharmacies can dispense Mifeprex or approved generic mifepristone, subject to certification and applicable state law.
Is Korlym interchangeable with abortion-dose mifepristone?
No. Korlym and Mifeprex contain the same active ingredient but have different approved indications, labeling, dosing frameworks, packaging, and risk-management requirements. They are not automatically interchangeable.
What event would most damage Korlym revenue?
Successful generic entry would create the clearest direct revenue threat. A generic approved with a substitutable label could produce rapid price erosion and loss of branded prescriptions, particularly because Corcept's historical revenue base has been concentrated in Korlym.
References
- U.S. Food and Drug Administration. (2000). Mifeprex approval letter and prescribing information.
- U.S. Food and Drug Administration. (2019). FDA approves first generic version of Mifeprex (mifepristone) tablets.
- U.S. Food and Drug Administration. (2012). Korlym prescribing information.
- Guttmacher Institute. (2024). Medication abortion accounted for 63% of all abortions in the United States in 2023.
- Corcept Therapeutics Incorporated. (2024). Annual report for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
- U.S. Food and Drug Administration. (2021). FDA updates REMS requirements for mifepristone for medical termination of early pregnancy.
- U.S. Food and Drug Administration. (2023). Mifepristone REMS modification.
- Supreme Court of the United States. (2024). Food and Drug Administration v. Alliance for Hippocratic Medicine, 602 U.S. ___ (2024).
